Vertex Hepatitis C Drug Works in More than 80% of Patients

Vertex Hepatitis C Drug Works in More than 80% of Patients

Vertex has announced the results of their Phase 2 Study C208 which explored the use of telaprevir-based regimen in hepatitis C patients. The study which showed more than 80% of patients responded is to be represented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which began yesterday in Boston.

Vertex has announced the results of their Phase 2 Study C208 which explored the use of telaprevir-based regimen in hepatitis C patients.

Source: 

Ramona Bates MD

$75 Million Awarded To Charles Drew University And Three Other Historically Black Institutions

The National Institutes of Health has awarded $75 million to Charles Drew University of Medicine and Science and three other historically black institutions to establish a medical research consortium to combat health disparities in minority and underserved populations. More at...

Onset Medical Performs First Human Use Of The SoloPath™ Endovascular Access Catheter To Deliver Percutaneous Aortic Heart Valve

Onset Medical Corporation announced the first human usage of its SoloPathTM Endovascular Access Catheter in a case performed by Eberhard Grube MD, Chief, Department of Cardiology/Angiology, Helios Heart Center, Siegburg in Germany. The primary clinical applications for the SoloPath family of Endovascular Access Catheters are to provide quicker and safer access of larger therapeutic devices through the femoral and iliac arteries of the leg into the larger aortic artery. Complete news at...